Core Viewpoint - The article highlights three dividend stocks—Abbott Laboratories, AbbVie, and Johnson & Johnson—as excellent options for passive income, emphasizing their strong dividend histories and solid business fundamentals. Group 1: Abbott Laboratories - Abbott Laboratories has a long history of dividend payments, dating back to 1924, and has increased its dividend for over 50 consecutive years [4] - The company currently pays a quarterly dividend of $0.59, which has risen by 146% over the past decade, averaging a compound annual growth rate of 9.4% [5] - Abbott's diverse operations across nutrition, diagnostics, pharmaceuticals, and medical devices contribute to its stability, with over $40 billion in revenue for the past four years and strong free cash flow of $6.7 billion [6][7] Group 2: AbbVie - AbbVie, spun off from Abbott in 2013, has maintained a strong dividend increase streak for 53 consecutive years, with a forward dividend yield of 3.64% [8] - The company has strategically invested in R&D and acquisitions, notably Allergan in 2020, to offset the decline in sales from its key drug Humira, which lost U.S. patent exclusivity in 2023 [9][10] - AbbVie's new drugs, Rinvoq and Skyrizi, are projected to generate combined sales of $31 billion by 2027, surpassing Humira's peak sales [10] Group 3: Johnson & Johnson - Johnson & Johnson is a leading healthcare company with a strong pharmaceutical business and a solid financial foundation, evidenced by its AAA credit rating from S&P Global [12] - The company has increased its dividends for 62 consecutive years, positioning it among the elite Dividend Kings, and is expected to continue this trend despite facing legal and regulatory challenges [13] - The defensive nature of the healthcare industry suggests that Johnson & Johnson will remain resilient during economic downturns, making it a strong choice for income-seeking investors [11]

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all persons or entities that: (a) sold or otherwise disposed of the publicly-trade ...

CANADA - 2025/04/03: In this photo illustration, the AbbVie logo is seen displayed on a smartphone ... More screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images AbbVie (NYSE:ABBV) stock has garnered recent attention following the FDA approval of Emrelis for adults with previously treated lung cancer who exhibit an overabundance of the c-Met protein. This protein is known to promote tumor growth and resistance to certain therapies. Thi ...

NEW YORK, May 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all persons or entities that: (a) sold or otherwise disposed of the publicly-traded com ...

DEADLINE: June 3, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/cerevel-therapeutics-holdings-inc-loss-submission- form/?id=148463&from=3 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ABBV during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to ...

NEW YORK, May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cerevel-therapeutics-holdings-inc-loss-submission-form/?id=148431&from=4 ...

I last wrote on AbbVie Inc. (NYSE: ABBV (NEOE: ABBV:CA ) and Pfizer Inc. (NYSE: PFE ) (NEOE: PFE:CA ) both back in March 2024. My last As you can tell, our core style is to provide actionable and unambiguous ideas from our independent research. If your share this investment style, check out Envision Early Retirement. It provides at least 1x in-depth articles per week on such ideas.We have helped our members not only to beat S&P 500 but also avoid heavy drawdowns despite the extreme volatilities in BOTH the ...

Company Overview - AbbVie has a strong leadership team with key executives including Jeff Stewart (EVP and Chief Commercialization Officer), Roopal Thakkar (EVP and R&D, Chief Scientific Officer), and Scott Reents (EVP and CFO) [1][2] Current Challenges - The company is experiencing some disruption due to external factors such as MFN (Most Favored Nation) policies and tariffs, which are impacting operational timelines [3][4] - There is an ongoing discussion about the level of disruption and the time it is taking to adapt to these changes, indicating that the company is actively involved in contingency planning [3][4]

AbbVie (ABBV) 2025 Conference Summary Company Overview - **Company**: AbbVie (ABBV) - **Date of Conference**: May 14, 2025 - **Key Speakers**: - Jeff Stewart, Executive Vice President, Chief Commercialization Officer - Rupl Thacker, Executive Vice President, R&D Chief Scientific Officer - Scott Rantz, Executive Vice President, Chief Financial Officer Key Points and Arguments Industry and Market Dynamics - **Disruption and Contingency Planning**: AbbVie acknowledges some disruption due to external factors but emphasizes that it is not affecting business execution. The management team is actively involved in contingency planning and assessing implications of changes in the market [4][6][9]. - **Drug Pricing Policies**: The company is taking the potential impact of new executive orders on drug pricing seriously, indicating that they are closely monitoring developments and preparing for various scenarios [6][8][9]. - **Pricing Equalization**: AbbVie believes that the concept of equalizing drug prices between the US and Europe is complex and may not be feasible due to different healthcare systems and pricing controls in Europe [10][11][12]. Financial Performance and Projections - **Revenue Guidance**: AbbVie has increased its revenue guidance for SKYRIZI and RINVOQ to a combined $31 billion by 2027, with SKYRIZI expected to generate $20 billion and RINVOQ $11 billion [55][56]. - **Immunology Market**: The immunology segment remains a significant revenue driver, with expectations of continued growth despite pricing pressures. The company anticipates low single-digit price degradation over the next five years [51][53]. Research and Development - **M&A Strategy**: AbbVie has been active in M&A, completing over 25 transactions since early 2024, focusing on filling its pipeline in neuroimmunology and oncology [31][32]. - **Obesity Market Entry**: AbbVie has entered the obesity market through a licensing deal with Gubra for an amylin compound, highlighting the potential for differentiation and long-term market opportunities [33][39]. Competitive Landscape - **Direct-to-Consumer Advertising**: AbbVie is the largest DTC advertiser in the pharmaceutical industry. The company is prepared to pivot its marketing strategies if regulations on DTC advertising are imposed [19][21][23]. - **Oral vs. Injectable Therapies**: AbbVie believes that while oral therapies are emerging, injectable products like SKYRIZI and RINVOQ will remain insulated from significant competition due to their efficacy and convenience [64]. Other Important Insights - **Tariffs and Supply Chain**: AbbVie is monitoring the potential impact of tariffs on its supply chain and is implementing mitigation strategies to ensure product availability [26][28][29]. - **Market Growth in Obesity**: The obesity market is expected to grow significantly, with AbbVie anticipating a cash pay component that will support its aesthetics business [48]. Conclusion AbbVie is strategically navigating a complex pharmaceutical landscape with a focus on maintaining growth through innovation, M&A, and effective contingency planning. The company is well-positioned to address challenges related to drug pricing, market competition, and regulatory changes while capitalizing on emerging opportunities in the obesity market and maintaining its leadership in immunology.

Core Insights - AbbVie announced the accelerated approval of EMRELIS™ (telisotuzumab vedotin-tllv) by the FDA for treating adult patients with advanced non-squamous non-small cell lung cancer (NSCLC) who have high c-Met protein overexpression and have received prior systemic therapy [1][2][3] - Lung cancer remains the leading cause of cancer-related deaths globally, with approximately 85% classified as NSCLC [2][3] - The approval is based on the overall response rate (ORR) and duration of response (DOR) from the Phase 2 LUMINOSITY study, which showed a 35% ORR and a median DOR of 7.2 months in patients with high c-Met overexpression [2][3] Company Overview - EMRELIS is AbbVie's first internally developed solid tumor medicine and represents a significant step in their commitment to developing cancer therapies [2][3] - The company is expanding its antibody-drug conjugate (ADC) portfolio to deliver targeted therapies to patients with difficult-to-treat tumors [2][3] - AbbVie is also focused on patient access, offering support programs to reduce out-of-pocket costs for eligible patients [6][21] Industry Context - The c-Met protein is overexpressed in approximately 25% of advanced EGFR wild type, non-squamous NSCLC patients, with about half of these patients having high c-Met overexpression [2][3] - There is a critical unmet need for targeted therapies in this patient population, as they often face poor prognosis and limited treatment options [2][3] - The FDA has also approved the Roche VENTANA® MET (SP44) RxDx Assay as a companion diagnostic to identify patients eligible for EMRELIS treatment [4][3]